Quantcast
Channel: Stock Blog Hub » Human Genome Sciences Inc.
Browsing all 32 articles
Browse latest View live

(HGSI) Human Genome Sciences Drug Under FDA Review

Recently, Human Genome Sciences Inc. (HGSI) suffered a setback when the US Food and Drug Administration (FDA) questioned the efficacy of its drug ABthrax (raxibacumab), meant for treating anthrax...

View Article



(HGSI) Human Genome Sciences Gets FDA Panel Request for ABthrax Data

A panel of experts of the US Food and Drug Administration (FDA) has recently asked for additional data to judge the efficacy of Human Genome Sciences Inc.’s (HGSI) anthrax infection treatment ABthrax...

View Article

(HGSI) Human Genome Sciences Reports Lower Q3 Loss

Human Genome Sciences, Inc. (HGSI) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a net loss of $74.2 million or...

View Article

(HGSI) Human Genome Sciences’ ABthrax Faces FDA Delay

Recently, Human Genome Sciences Inc. (HGSI) announced that the U.S. Food and Drug Administration (FDA) delayed the approval of ABthrax (raxibacumab), the company’s candidate for anthrax treatment,...

View Article

(HGSI) Human Genome Sciences Begins Trial

Recently, Human Genome Sciences, Inc. (HGSI) and Aegera Therapeutics announced the initiation of dosing in a phase I clinical trial to evaluate the safety and tolerability of its lead...

View Article


(HGSI) Human Genome Sciences to Sell 12.5 Million Shares

Human Genome Sciences Inc. (HGSI) announced that it intends to sell up to 12.5 million shares to raise money for the development of its potential blockbuster lupus drug Benlysta and other business...

View Article

(HGSI) Human Genome Sciences Seeks Approval For Hepatitis C Treatment

Human Genome Sciences, Inc. (HGSI) recently announced the submission of a Marketing Authorization Application, [MAA], to the European Medicines Agency (EMEA) seeking marketing approval of Joulferon...

View Article

(HGSI) Human Genome Sciences to Seek Drug Approval in Second Quarter

Human Genome Sciences Inc. (HGSI) announced recently that it intends to seek approval for its potential blockbuster lupus drug candidate Benlysta during the second quarter of 2010 in the United States...

View Article


(DNDN) These Biotech Stocks Are Just What the Doctor Ordered

by Louise Harris, Investment U Research Thursday, January 28, 2010 They say that one in every nine women will get breast cancer. It’s a staggering statistic, just like the equally frightening claim...

View Article


(HGSI) Human Genome Sciences Pipeline Bigger than Earnings

Human Genome Sciences, Inc. (HGSI) is expected to report fourth quarter as well as fiscal 2009 results shortly. We expect that the company will report a loss of 10 cents per share for the fourth...

View Article

(HGSI) Human Genome Sciences Reports Lower Fourth Quarter Loss

Human Genome Sciences, Inc. (HGSI) reported fourth quarter 2009 net loss of $9.7 million or 6 cents per share, narrower than the Zacks Consensus Estimate of 9 cents and the year-ago loss of $61.9...

View Article

(HGSI) Human Genome Sciences Joins Forces With Swedish To Commercialize New...

Human Genome Sciences, Inc. (HGSI) and BioInvent International AB, a Swedish pharmaceutical research company, have joined forces to discover, develop and commercialize therapeutic monoclonal antibodies...

View Article

(HGSI) Human Genome Sciences Releases Encouraging Data on Zalbin

Recently, Human Genome Sciences Inc. (HGSI) announced interim results on hepatitis C candidate Zalbin from a mid-stage study. The study evaluated the safety and efficacy of Zalbin. The results revealed...

View Article


(HGSI) Human Genome Sciences Gets Setback From Partner Novartis AG

Recently, Human Genome Sciences Inc. (HGSI) received a setback when the Marketing Authorization Application (MAA) for its hepatitis C candidate Joulferon (albinterferon alfa-2b) was withdrawn by its...

View Article

(HGSI) Human Genome Sciences Announces Bad News for Lupus Candidate

Recently, Human Genome Sciences, Inc. (HGSI) announced that its potential blockbuster lupus drug candidate Benlysta (belimumab) failed to meet its secondary goals in a late-stage trial BLISS-76. Human...

View Article


(HGSI) Human Genome Sciences Reports Wider-Than-Expected Loss

Human Genome Sciences Inc’s (HGSI) first quarter 2010 net loss of 26 cents per share was wider than the Zacks Consensus Estimate of 20 cents. The company earned 56 cents per share (excluding special...

View Article

(HGSI) Human Genome Sciences’ Earnings Scorecard

Human Genome Sciences, Inc.’s (HGSI) first quarter 2010 net loss of 26 cents per share was wider than the Zacks Consensus Estimate of a loss of 20 cents. The company earned 56 cents in the year-ago...

View Article


(HGSI) Human Genome Sciences Seeks European Approval For Lupus Drug

Human Genome Sciences Inc. (HGSI) recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking marketing approval for its potential blockbuster lupus...

View Article

(HGSI) Human Genome Sciences Seeks Lupus Drug FDA Approval

Human Genome Sciences Inc. (HGSI) recently submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking marketing approval for its potential blockbuster lupus...

View Article

(HGSI) Human Genome Sciences Earns Priority Review for Benlysta

Human Genome Sciences, Inc. (HGSI) received a huge boost when its potential blockbuster drug candidate Benlysta was granted priority review status by the US Food and Drug Administration (FDA)....

View Article
Browsing all 32 articles
Browse latest View live




Latest Images